| scPharmaceuticals Inc. (SCPH) Q1 2025 Earnings Call Transcript |
scPharmaceuticals Inc. (NASDAQ:SCPH ) Q1 2025 Earnings Conference Call May 14, 2025 4:30 PM ET Company Participants William Thorpe - Investor Relations John Tucker - Chief Executive Officer Steve Parsons - Senior Vice President of Commercial Rachael Nokes - Chief Financial Officer Conference Call Participants Roanna Ruiz - Leerink Partners Stacy Ku - TD Cowen Douglas Tsao - H.C. Wainwright Chase Knickerbocker - Craig-Hallum Operator Good afternoon and welcome to scPharmaceuticals First Quarter 2025 Earnings Conference Call. |
seekingalpha.com |
2025-05-15 04:15:31 |
Czytaj oryginał (ang.) |
| ScPharmaceuticals, Inc. (SCPH) Reports Q1 Loss, Misses Revenue Estimates |
ScPharmaceuticals, Inc. (SCPH) came out with a quarterly loss of $0.34 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to loss of $0.36 per share a year ago. |
zacks.com |
2025-05-14 22:15:36 |
Czytaj oryginał (ang.) |
| scPharmaceuticals Inc. Reports First Quarter 2025 Financial Results and Provides Business Update |
Generated net FUROSCIX ® revenue of $11.8 million in the first quarter of 2025 Formally launched FUROSCIX in second approved indication, Chronic Kidney Disease, in April 2025 Autoinjector on track for sNDA submission in Q3 2025; designed to reduce treatment time from five hours to less than ten seconds Cash and cash equivalents of $57.5 million as of March 31, 2025 Investor conference call and webcast today, Wednesday, May 14 th , at 4:30pm ET BURLINGTON, Mass., May 14, 2025 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH) (the “Company”), a pharmaceutical company committed to revolutionizing cardiorenal healthcare through patient-centric innovations, today reported financial results for the first quarter ended March 31, 2025, and provided a business update. |
globenewswire.com |
2025-05-14 20:01:00 |
Czytaj oryginał (ang.) |
| scPharmaceuticals to Announce First Quarter 2025 Financial Results After the Market Close on May 14, 2025 |
Management to host conference call and webcast, after-market on May 14, 2025, at 4:30 p.m. ET Management to host conference call and webcast, after-market on May 14, 2025, at 4:30 p.m. ET |
globenewswire.com |
2025-05-07 20:01:00 |
Czytaj oryginał (ang.) |
| scPharmaceuticals Announces Participation in Three Upcoming Investor Conferences |
BURLINGTON, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH) (the “Company”), a pharmaceutical company committed to revolutionizing cardiorenal healthcare through patient-centric innovations, today announced that John Tucker, President and Chief Executive Officer, will participate in the following upcoming investor conferences: |
globenewswire.com |
2025-05-01 20:01:00 |
Czytaj oryginał (ang.) |
| scPharmaceuticals Inc. (SCPH) Q4 2024 Earnings Call Transcript |
scPharmaceuticals Inc. (NASDAQ:SCPH ) Q4 2024 Results Conference Call March 19, 2025 4:30 PM ET Company Participants Nick Colangelo - Investor Relations John Tucker - Chief Executive Officer Steve Parsons - Senior Vice President of Commercial Rachael Nokes - Chief Financial Officer Conference Call Participants Stacy Ku - TD Cowen Glen Santangelo - Jefferies Roanna Ruiz - Leerink Partners Douglas Tsao - H.C. Wainwright Naz Rahman - Maxim Group Chase Knickerbocker - Craig-Hallum Operator Good afternoon, and welcome to scPharmaceuticals Fourth Quarter and Full Year 2024 Earnings Conference Call. |
seekingalpha.com |
2025-03-19 21:13:03 |
Czytaj oryginał (ang.) |
| ScPharmaceuticals, Inc. (SCPH) Reports Q4 Loss, Tops Revenue Estimates |
ScPharmaceuticals, Inc. (SCPH) came out with a quarterly loss of $0.35 per share versus the Zacks Consensus Estimate of a loss of $0.40. This compares to loss of $0.35 per share a year ago. |
zacks.com |
2025-03-19 20:10:22 |
Czytaj oryginał (ang.) |
| scPharmaceuticals Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update |
scPharmaceuticals generated fourth quarter 2024 net FUROSCIX ® revenue of $12.2 million, and full year 2024 revenue of $36.3 million |
globenewswire.com |
2025-03-19 18:01:00 |
Czytaj oryginał (ang.) |
| scPharmaceuticals to Announce Fourth Quarter and Full Year 2024 Financial Results on Wednesday, March 19, 2025 |
Management to host conference call and webcast, after-market on March 19, 2025, at 4:30 p.m. ET Management to host conference call and webcast, after-market on March 19, 2025, at 4:30 p.m. ET |
globenewswire.com |
2025-03-12 18:01:00 |
Czytaj oryginał (ang.) |
| scPharmaceuticals Announces FDA Approval of Supplemental New Drug Application Expanding the FUROSCIX® Indication to Include the Treatment of Edema in Patients with Chronic Kidney Disease |
FDA approves scPharmaceuticals' supplemental New Drug Application to expand the FUROSCIX indication to include the treatment of edema in adult patients with chronic kidney disease, including nephrotic syndrome |
globenewswire.com |
2025-03-06 18:01:00 |
Czytaj oryginał (ang.) |
| ScPharmaceuticals, Inc. (SCPH) Expected to Beat Earnings Estimates: Should You Buy? |
ScPharmaceuticals (SCPH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
zacks.com |
2025-03-05 13:00:41 |
Czytaj oryginał (ang.) |
| scPharmaceuticals Announces Participation in Two Upcoming Investor Conferences |
BURLINGTON, Mass., Feb. 26, 2025 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH) (the “Company”), a pharmaceutical company committed to revolutionizing cardiorenal healthcare through patient-centric innovations, today announced that John Tucker, President and Chief Executive Officer, will present at the following upcoming investor conferences: |
globenewswire.com |
2025-02-26 18:01:00 |
Czytaj oryginał (ang.) |
| scPharmaceuticals to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference |
BURLINGTON, Mass., Feb. 05, 2025 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH) (the “Company”), a pharmaceutical company committed to revolutionizing cardiorenal healthcare through patient-centric innovations, today announced that John Tucker, President & Chief Executive Officer, will present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on Wednesday, February 12 at 2:40PM ET. |
globenewswire.com |
2025-02-05 18:01:00 |
Czytaj oryginał (ang.) |
| scPharmaceuticals Provides Preliminary Unaudited Fourth Quarter and Full Year 2024 Financial Results |
Preliminary unaudited fourth quarter 2024 net revenue expected to be approximately $12 million to $12.3 million, representing 99% growth over Q4 2023 at the mid-point of the range |
globenewswire.com |
2025-01-10 10:00:00 |
Czytaj oryginał (ang.) |
| scPharmaceuticals Inc. (SCPH) Q3 2024 Earnings Call Transcript |
scPharmaceuticals Inc. (NASDAQ:SCPH ) Q3 2024 Earnings Conference Call November 13, 2024 4:30 PM ET Company Participants Nick Colangelo - Investor Relations John Tucker - Chief Executive Officer Steve Parsons - Senior Vice President of Commercial Rachael Nokes - Chief Financial Officer Conference Call Participants Anupam Leesy - Leerink Partners Stacy Ku - TD Cowen Douglas Tsao - H.C. Wainwright Chase Knickerbocker - Craig-Hallum Operator Good afternoon, and welcome to scPharmaceuticals' Third Quarter 2024 Earnings Conference Call. |
seekingalpha.com |
2024-11-13 21:05:23 |
Czytaj oryginał (ang.) |
| ScPharmaceuticals, Inc. (SCPH) Reports Q3 Loss, Lags Revenue Estimates |
ScPharmaceuticals, Inc. (SCPH) came out with a quarterly loss of $0.37 per share versus the Zacks Consensus Estimate of a loss of $0.30. This compares to loss of $0.41 per share a year ago. |
zacks.com |
2024-11-13 20:20:24 |
Czytaj oryginał (ang.) |
| scPharmaceuticals Inc. Reports Third Quarter 2024 Financial Results and Provides Business Update |
Generated 3Q 2024 net FUROSCIX ® revenue of $10.0 million, up 164% from Q3 2023 Received approval of label expansion to include New York Heart Association (NYHA) Class IV Patients Announced positive pharmacokinetic/pharmacodynamic (PK/PD) data on Autoinjector program Completed $125 million transformative financing in a combination of debt and equity that is anticipated to fund the Company through expected profitability Company to host investor conference call and webcast today, Wednesday, November 13 th , at 4:30pm ET BURLINGTON, Mass., Nov. 13, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company committed to revolutionizing cardiorenal healthcare through patient-centric innovations, today announced financial results for the third quarter ended September 30, 2024, and provided a business update. |
globenewswire.com |
2024-11-13 18:01:00 |
Czytaj oryginał (ang.) |
| scPharmaceuticals to Announce Third Quarter 2024 Financial Results on Wednesday, November 13, 2024 |
Management to host conference call and webcast, after-market on November 13, 2024, at 4:30 p.m. ET Management to host conference call and webcast, after-market on November 13, 2024, at 4:30 p.m. ET |
globenewswire.com |
2024-11-06 18:01:00 |
Czytaj oryginał (ang.) |
| scPharmaceuticals to Host Key Opinion Leader (KOL) Webinar on October 22, 2024 |
Webinar to focus on a nephrologist's perspective on the use of FUROSCIX for fluid overload in heart failure and potential use in chronic kidney disease Webinar to focus on a nephrologist's perspective on the use of FUROSCIX for fluid overload in heart failure and potential use in chronic kidney disease |
globenewswire.com |
2024-10-15 12:30:00 |
Czytaj oryginał (ang.) |
| Does scPharmaceuticals (SCPH) Have the Potential to Rally 291.9% as Wall Street Analysts Expect? |
The mean of analysts' price targets for scPharmaceuticals (SCPH) points to a 291.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock. |
zacks.com |
2024-08-16 14:55:20 |
Czytaj oryginał (ang.) |
| scPharmaceuticals Inc. (SCPH) Q2 2024 Earnings Call Transcript |
scPharmaceuticals Inc. (NASDAQ:SCPH ) Q2 2024 Earnings Call Transcript August 14, 2024 4:30 PM ET Company Participants PJ Kelleher - IR John Tucker - CEO Steve Parsons - SVP, Commercial Rachael Nokes - CFO Conference Call Participants Roanna Ruiz - Leerink Partners Chase Knickerbocker - Craig-Hallum Capital Group Operator Greetings, and welcome to the scPharmaceuticals Second Quarter 2024 Earnings Conference Call. At this time all participants are in a listen-only mode. |
seekingalpha.com |
2024-08-15 09:10:10 |
Czytaj oryginał (ang.) |
| ScPharmaceuticals, Inc. (SCPH) Reports Q2 Loss, Tops Revenue Estimates |
ScPharmaceuticals, Inc. (SCPH) came out with a quarterly loss of $0.44 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.36 per share a year ago. |
zacks.com |
2024-08-14 22:21:05 |
Czytaj oryginał (ang.) |
| scPharmaceuticals Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update |
Generated 2Q 2024 net FUROSCIX® revenue of $8.1 million, up 33% sequentially from Q1 Completed financing that extends our cash runway through expected profitability Advanced multiple FUROSCIX growth initiatives including label expansion for heart failure, sNDA submission for CKD, and positive topline pivotal PK data for our Autoinjector Company to host investor conference call and webcast today, Wednesday, August 14 th , at 4:30pm ET BURLINGTON, Mass., Aug. 14, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced financial results for the second quarter ended June 30, 2024, and provided a business update. |
globenewswire.com |
2024-08-14 20:01:00 |
Czytaj oryginał (ang.) |
| scPharmaceuticals Announces Pricing of $50.0 Million Public Offering |
BURLINGTON, Mass., Aug. 12, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced the pricing of an underwritten public offering of 12,000,000 shares of its common stock at a public offering price of $4.00 per share and, to select investors, in lieu of common stock, pre-funded warrants to purchase up to 500,000 shares of common stock at a purchase price of $3.999 per underlying share, for gross proceeds of approximately $50.0 million, before deducting underwriting discounts and commissions and other offering expenses and excluding the exercise of the pre-funded warrants. The pre-funded warrants have an exercise price of $0.001 per share. All of the shares and the pre-funded warrants are being offered by scPharmaceuticals. In addition, the Company has granted the underwriters a 30-day option to purchase up to an additional 1,875,000 shares of common stock from the Company at the public offering price, less the underwriting discounts and commissions. The offering is expected to close on August 13, 2024, subject to the satisfaction of customary closing conditions. |
globenewswire.com |
2024-08-12 13:48:00 |
Czytaj oryginał (ang.) |
| scPharmaceuticals Announces Non-Dilutive Financings Totaling Up to $125 Million with Perceptive Advisors |
scPharmaceuticals received $75 million through a combination of debt and royalty financings at close, with access to an additional $50 million |
globenewswire.com |
2024-08-12 10:05:00 |
Czytaj oryginał (ang.) |
| scPharmaceuticals Announces FDA Approval of Supplemental New Drug Application Expanding the FUROSCIX Indication in Heart Failure |
FUROSCIX is now indicated for the treatment of congestion due to fluid overload in adult patients with chronic heart failure, regardless of New York Heart Association (NYHA) functional class |
globenewswire.com |
2024-08-12 10:04:00 |
Czytaj oryginał (ang.) |
| scPharmaceuticals Announces Positive Topline Study Results for SCP-111 (Furosemide 80 mg/1 mL) Autoinjector |
SCP-111 Autoinjector achieved primary pharmacokinetic and secondary pharmacodynamic endpoints The autoinjector is being developed to deliver a subcutaneous injection of furosemide as an alternative option to the FDA approved FUROSCIX on-body infusor presentation Company targeting Supplemental New Drug Application (sNDA) submission to the FDA by year-end 2024 BURLINGTON, Mass., Aug. 12, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH) (the “Company”), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced positive topline results from the pharmacokinetic (PK) study of SCP-111, an investigational, low volume, pH neutral formulation of furosemide administered via an autoinjector as an alternative to the current on-body infusor used with FUROSCIX. |
globenewswire.com |
2024-08-12 10:02:00 |
Czytaj oryginał (ang.) |
| scPharmaceuticals Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants |
BURLINGTON, Mass., Aug. 12, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH) (the “Company”), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced a proposed underwritten public offering of shares (“Shares”) of its common stock or, in lieu of Shares, pre-funded warrants (the “Pre-Funded Warrants”) to purchase Shares (the “Offering”). scPharmaceuticals also expects to grant the underwriters a 30-day option to purchase up to an additional 15% of Shares offered in the Offering. All Shares and Pre-Funded Warrants to be sold in the Offering will be offered by scPharmaceuticals. The Offering is subject to market and other conditions, and there can be no assurance as to whether or when the Offering may be completed, or as to the actual size or terms of the offering. |
globenewswire.com |
2024-08-12 10:00:00 |
Czytaj oryginał (ang.) |
| 7 Short-Squeeze Stocks That Could Beat Down the Bears |
Short-squeeze stocks represent one of the boldest forms of contrarianism available. Simply put, it's a showdown between the bears that are attempting to profit from the downturn of a public enterprise. |
investorplace.com |
2024-07-15 15:57:15 |
Czytaj oryginał (ang.) |
| scPharmaceuticals to Present at the Jefferies Global Healthcare Conference |
BURLINGTON, Mass., May 29, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced that John Tucker, President & Chief Executive Officer, will present at the Jefferies Global Healthcare Conference on Wednesday, June 5 at 5:00PM ET. Mr. Tucker will also be meeting with investors that day. |
globenewswire.com |
2024-05-29 20:01:00 |
Czytaj oryginał (ang.) |
| scPharmaceuticals Inc. (SCPH) Q1 2024 Earnings Call Transcript |
scPharmaceuticals Inc. (NASDAQ:SCPH ) Q1 2024 Earnings Call Transcript May 14, 2024 4:30 PM ET Company Participants PJ Kelleher - IR John Tucker - CEO Steve Parsons - SVP of Commercial Rachael Nokes - CFO Conference Call Participants Glen Santangelo - Jefferies Stacy Ku - TD Cowen Roanna Ruiz - Leerink Partners Chase Knickerbocker - Craig-Hallum Capital Naz Rahman - Maxim Group Douglas Tsao - HC Wainwright Operator Good afternoon, ladies and gentlemen, and welcome to the scPharmaceuticals First Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode. |
seekingalpha.com |
2024-05-14 23:02:02 |
Czytaj oryginał (ang.) |
| ScPharmaceuticals, Inc. (SCPH) Reports Q1 Loss, Lags Revenue Estimates |
ScPharmaceuticals, Inc. (SCPH) came out with a quarterly loss of $0.36 per share versus the Zacks Consensus Estimate of a loss of $0.45. This compares to loss of $0.30 per share a year ago. |
zacks.com |
2024-05-14 22:20:20 |
Czytaj oryginał (ang.) |
| scPharmaceuticals Inc. Reports First Quarter 2024 Financial Results and Provides Business Update |
Generated 1Q 2024 net FUROSCIX® revenue of $6.1 million, despite an estimated 10% impact to doses filled resulting from the Change Healthcare cyberattack |
globenewswire.com |
2024-05-14 20:01:00 |
Czytaj oryginał (ang.) |
| scPharmaceuticals to Present at the H.C. Wainwright 2nd Annual BioConnect Investor Conference |
BURLINGTON, Mass., May 13, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced that John Tucker, President & Chief Executive Officer, will present at the H.C. Wainwright 2nd Annual BioConnect Investor Conference, which will be held at the NASDAQ World Headquarters in New York on Monday, May 20, at 11:00AM ET. Mr. Tucker will also be meeting with investors during the event. |
globenewswire.com |
2024-05-13 20:05:00 |
Czytaj oryginał (ang.) |